Exelixis
EXEL
#1324
Rank
NZ$30.24 B
Marketcap
NZ$123.93
Share price
1.25%
Change (1 day)
68.40%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2023 (TTM): NZ$0.46

According to Exelixis's latest financial reports the company's current EPS (TTM) is NZ$6.16. In 2022 the company made an earnings per share (EPS) of NZ$1.02 a decrease over its 2021 EPS that were of NZ$1.32.

EPS history for Exelixis from 2000 to 2023

Annual EPS

Year EPS Change
2023 (TTM)NZ$0.46-54.41%
2022NZ$1.02-22.97%
2021NZ$1.32100%
2020NZ$0.66-65.09%
2019NZ$1.89-53.91%
2018NZ$4.10333.96%
2017NZ$0.94-260.61%
2016NZ-$0.59-58.75%
2015NZ-$1.43-42.45%
2014NZ-$2.485.3%
2013NZ-$2.3543.48%
2012NZ-$1.64-264.29%
2011NZ$1.00-165.88%
2010NZ-$1.51-32.54%
2009NZ-$2.24-17.65%
2008NZ-$2.7375.86%
2007NZ-$1.55-25.64%
2006NZ-$2.088.33%
2005NZ-$1.92-42.86%
2004NZ-$3.3730.34%
2003NZ-$2.58-5.23%
2002NZ-$2.73-0.65%
2001NZ-$2.74-51.88%
2000NZ-$5.70

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Johnson & Johnson
JNJ
NZ$11.91 93.20%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
NZ$1.35-78.03%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
NZ$28.89 368.79%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
NZ$3.39-45.00%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
NZ$1.77-71.31%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
NZ$8.05 30.64%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
NZ$5.13-16.84%๐Ÿ‡ฌ๐Ÿ‡ง UK
Curis
CRIS
NZ-$25.33-510.98%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
NZ-$1.50-124.28%๐Ÿ‡บ๐Ÿ‡ธ USA